159 related articles for article (PubMed ID: 17961191)
1. Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate.
Jiang X; Galettis P; Links M; Mitchell PL; McLachlan AJ
Br J Clin Pharmacol; 2008 Mar; 65(3):326-33. PubMed ID: 17961191
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
Sugiyama E; Kaniwa N; Kim SR; Hasegawa R; Saito Y; Ueno H; Okusaka T; Ikeda M; Morizane C; Kondo S; Yamamoto N; Tamura T; Furuse J; Ishii H; Yoshida T; Saijo N; Sawada J
Clin Pharmacokinet; 2010 Aug; 49(8):549-58. PubMed ID: 20608756
[TBL] [Abstract][Full Text] [Related]
3. [Population pharmacokinetics of gemcitabine applied to personalize the dosage used in cancer patients].
Ramón-López A; Escudero-Ortiz V; Duart-Duart MJ; Pérez-Ruixo JJ; Valenzuela B
Farm Hosp; 2012; 36(4):194-206. PubMed ID: 22078546
[TBL] [Abstract][Full Text] [Related]
4. SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.
Khatri A; Williams BW; Fisher J; Brundage RC; Gurvich VJ; Lis LG; Skubitz KM; Dudek AZ; Greeno EW; Kratzke RA; Lamba JK; Kirstein MN
Br J Cancer; 2014 Jan; 110(2):304-12. PubMed ID: 24300978
[TBL] [Abstract][Full Text] [Related]
5. Is age just a number? A population pharmacokinetic study of gemcitabine.
Boosman RJ; Crombag MBS; van Erp NP; Beijnen JH; Steeghs N; Huitema ADR
Cancer Chemother Pharmacol; 2022 May; 89(5):697-705. PubMed ID: 35426526
[TBL] [Abstract][Full Text] [Related]
6. Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates.
Kerr JZ; Berg SL; Dauser R; Nuchtern J; Egorin MJ; McGuffey L; Aleksic A; Blaney S
Cancer Chemother Pharmacol; 2001 May; 47(5):411-4. PubMed ID: 11391856
[TBL] [Abstract][Full Text] [Related]
7. Coadministration of oxaliplatin does not influence the pharmacokinetics of gemcitabine.
Pappas P; Mavroudis D; Nikolaidou M; Georgoulias V; Marselos M
Anticancer Drugs; 2006 Nov; 17(10):1185-91. PubMed ID: 17075318
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer.
Fan Y; Lin NM; Ma SL; Luo LH; Fang L; Huang ZY; Yu HF; Wu FQ
Acta Pharmacol Sin; 2010 Jun; 31(6):746-52. PubMed ID: 20523345
[TBL] [Abstract][Full Text] [Related]
9. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma.
Faivre S; Le Chevalier T; Monnerat C; Lokiec F; Novello S; Taieb J; Pautier P; Lhommé C; Ruffié P; Kayitalire L; Armand JP; Raymond E
Ann Oncol; 2002 Sep; 13(9):1479-89. PubMed ID: 12196375
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach.
Serdjebi C; Gattacceca F; Seitz JF; Fein F; Gagnière J; François E; Abakar-Mahamat A; Deplanque G; Rachid M; Lacarelle B; Ciccolini J; Dahan L
Ther Drug Monit; 2017 Jun; 39(3):290-296. PubMed ID: 28346313
[TBL] [Abstract][Full Text] [Related]
11. Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule.
Peters GJ; Clavel M; Noordhuis P; Geyssen GJ; Laan AC; Guastalla J; Edzes HT; Vermorken JB
J Chemother; 2007 Apr; 19(2):212-21. PubMed ID: 17434832
[TBL] [Abstract][Full Text] [Related]
12. Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice.
Veltkamp SA; Pluim D; van Tellingen O; Beijnen JH; Schellens JH
Drug Metab Dispos; 2008 Aug; 36(8):1606-15. PubMed ID: 18490432
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous infusion.
Freise KJ; Martín-Jiménez T
J Vet Pharmacol Ther; 2006 Apr; 29(2):147-52. PubMed ID: 16515669
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment.
Kiani A; Köhne CH; Franz T; Passauer J; Haufe T; Gross P; Ehninger G; Schleyer E
Cancer Chemother Pharmacol; 2003 Mar; 51(3):266-70. PubMed ID: 12655447
[TBL] [Abstract][Full Text] [Related]
15. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors.
Mavroudis D; Pappas P; Kouroussis C; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Vardakis N; Nikolaidou M; Samonis G; Marselos M; Georgoulias V
Ann Oncol; 2003 Feb; 14(2):304-12. PubMed ID: 12562660
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E
Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion.
Alharbi AF; Kratzke RA; D'Cunha J; Maddaus MA; Sanghavi K; Kirstein MN
Cancer Chemother Pharmacol; 2019 Feb; 83(2):387-391. PubMed ID: 30542769
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of combination of intravenous gemcitabine, oxaliplatin, and 5-FU with daily oral thalidomide (GOFT) in metastatic/locally advanced pancreatic carcinoma patients.
Shan YS; Lin PW
Hepatogastroenterology; 2007; 54(79):2141-5. PubMed ID: 18251177
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine and oxaliplatin in patients with metastatic breast cancer resistant to or pretreated with both anthracyclines and taxanes: clinical and pharmacokinetic data.
Airoldi M; Cattel L; Passera R; Pedani F; Delprino L; Micari C
Am J Clin Oncol; 2006 Oct; 29(5):490-4. PubMed ID: 17023785
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression.
Shibata S; Chow W; Frankel P; Juhasz A; Leong L; Lim D; Margolin K; Morgan R; Newman E; Somlo G; Yen Y; Synold T; Gandara D; Lenz HJ; Doroshow J
Cancer Chemother Pharmacol; 2007 Mar; 59(4):549-57. PubMed ID: 17051371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
